Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2017-12-11
Target enrollment:
Participant gender:
Summary
To determine the efficacy (as measured by progression-free survival [PFS] rate at 8 weeks) of
regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory
to standard therapies and who were never exposed to antiangiogenic therapy.